Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (FUDANZHANGJIANG) has signed an agreement with Shanghai Pudong Development Bank (SPD Bank) to subscribe for a principal-guaranteed structured deposit valued at RMB210.00 million, deploying surplus operating cash to enhance short-term returns.

The 87-day product, effective 3 April 2026, offers a floating annualized return ranging between 0.70% and 2.05%, linked to the EUR/USD exchange rate. The actual yield will be determined on 25 June 2026, using BFIX Bloomberg fixing prices: • If the observation price is below 91.61% of the starting price, the annualized return is 0.70%. • If between 91.61% and 104.58% of the starting price, the return is 1.85%. • If at or above 104.58% of the starting price, the return rises to 2.05%.

SPD Bank classifies the product as low risk, and the principal is guaranteed; however, the Company cannot exercise early redemption, while the bank retains termination rights under force majeure or public-interest considerations.

According to Hong Kong Listing Rules, at least one applicable percentage ratio for the RMB210.00 million placement exceeds 5% but remains below 25%, making the deal a disclosable transaction. Consequently, it requires public reporting and announcement but not shareholder approval.

FUDANZHANGJIANG’s board stated that deploying temporary idle funds into the structured deposit aligns with its objectives of capital preservation, liquidity assurance, and enhanced returns compared with standard fixed deposits in mainland China banks. The directors, including independent non-executive members, consider the terms fair, reasonable, and in the interests of the company and its shareholders.